CRVS

Corvus Pharmaceuticals, Inc. CRVS

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.0M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Net income

$-17.96M

Quarter to Jun 30

Free cash flow

$-15.98M

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$1.06B total
ORBIMED ADVISORS LLC
$107.05M0.0%
BlackRock, Inc.
$106.65M+15.9%
STATE STREET CORP
$66.84M+25.5%
PRICE T ROWE ASSOCIATES INC /MD/
$56.61M+29.9%
VANGUARD CAPITAL MANAGEMENT LLC
$49.19M+1.8%
ADAMS STREET PARTNERS LLC
$48.94M0.0%
Vivo Capital, LLC
$41.92M0.0%
WELLINGTON MANAGEMENT GROUP LLP
$40.81M+17.8%
PERCEPTIVE ADVISORS LLC
$39.85M+16.4%
Deep Track Capital, LP
$37.23M0.0%
BRAIDWELL LP
$31.77M+21.3%
GEODE CAPITAL MANAGEMENT, LLC
$27.70M+8.2%
Foresite Capital Management VI LLC
$27.36M0.0%
GOLDMAN SACHS GROUP INC
$23.55M+2.3%
Hood River Capital Management LLC
$23.48M+17.7%
MORGAN STANLEY
$20.09M-46.2%
Boxer Capital Management, LLC
$16.43M0.0%
Catalio Capital Management, LP
$16.15M+21.2%
MILLENNIUM MANAGEMENT LLC
$15.66M+21.0%
VANGUARD PORTFOLIO MANAGEMENT LLC
$12.17M+21.6%
TWO SIGMA INVESTMENTS, LP
$11.73M+45.4%
BANK OF AMERICA CORP /DE/
$11.32M+219.7%
ADAGE CAPITAL PARTNERS GP, L.L.C.
$11.21M0.0%
Eversept Partners, LP
$11.18MNew
EMERALD ADVISERS, LLC
$10.24M-0.1%
See all 174 institutional holders →
Reading the latest SEC filing…

Key Metrics

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

ROIC

Q2 2026
EDGAR

Free Cash Flow

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/CRVS

Earnings Per Share

13fpro.ai/company/CRVS

Loading ratio trend…

CRVS insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About Corvus Pharmaceuticals, Inc. (CRVS): stock profile, AI score and financials

Corvus Pharmaceuticals, Inc. (CRVS) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. CRVS is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.0m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (Q2 2026), Corvus Pharmaceuticals, Inc. reports net income of $-18.0M, free cash flow of $-16.0M. Top institutional holders of CRVS by reported 13-F value include ORBIMED ADVISORS, BlackRock, STATE STREET, based on the most recent SEC filings. CRVS trades on the Nasdaq exchange and files with the SEC under CIK 1626971. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CRVS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Corvus Pharmaceuticals, Inc. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1626971 →